Table 1 Baseline characteristics of the included patients
From: Molecular characterization of breast cancer: a potential novel immune-related lncRNAs signature
Variables | Primary cohort | Validation cohort | P value |
|---|---|---|---|
No. (%) | No. (%) | ||
No. of patients | 911 | 456 | Â |
Age (years) | 58 (48, 66) | 57 (48, 67) | 0.862 |
 T stage | 0.699 | ||
 T1 | 248 (27.2) | 125 (27.4) |  |
 T2 | 529 (58.1) | 254 (55.7) |  |
 T3 | 110 (12.1) | 65 (14.3) |  |
 T4 | 24 (2.6) | 12 (2.6) |  |
N stage | 0.266 | ||
 N0 | 435 (47.8) | 224 (49.1) |  |
 N1 | 306 (33.6) | 150 (32.9) |  |
 N2 | 95 (10.4) | 48 (10.5) |  |
 N3 | 65 (7.1) | 34 (7.5) |  |
 Nx | 10 (1.1) | 0 (0) |  |
TNM stage | 0.878 | ||
 I | 161 (17.7) | 82 (18.0) |  |
 II | 527 (57.8) | 261 (57.2) |  |
 III | 206 (22.6) | 107 (23.5) |  |
 Unknown | 17 (1.9) | 6 (1.3) |  |
ER status | 0.723 | ||
 Negative | 192 (21.1) | 90 (19.7) |  |
 Positive | 682 (74.8) | 350 (76.8) |  |
 Unknown | 37 (4.1) | 16 (3.5) |  |
PR status | 0.920 | ||
 Negative | 275 (30.2) | 137 (30.0) |  |
 Positive | 598 (65.6) | 302 (66.2) |  |
 Unknown | 38 (4.2) | 17 (3.7) |  |
HER2 status | 0.265 | ||
 Negative | 653 (71.7) | 340 (74.6) |  |
 Positive | 155 (17.0) | 62 (13.6) |  |
 Unknown | 103 (11.3) | 54 (11.8) |  |
Molecular subtype | 0.495 | ||
 HR+/HER2- | 523 (57.4) | 277 (60.7) |  |
 HR+/HER2 +  | 124 (13.6) | 52 (11.4) |  |
 HR−/HER2+ | 31 (3.4) | 10 (2.2) |  |
 TNBC | 129 (14.2) | 62 (13.6) |  |
 Unknown | 104 (11.4) | 55 (12.1) |  |